

This listing of claims will replace all prior versions, and listings, of claims in our amendments or responses to Office actions.

Listing of Claims:

1. (Currently amended) A method of treating a human subject experiencing a physiological disorder comprising administering an effective amount of an antagonist [[of]] antibody that specifically binds to DCRS5 (SEQ ID NO: 2), or antigen binding fragment thereof, wherein the disorder comprises[:
a)] an inflammatory bowel disorder (IBD).
2. (Cancelled)
3. (Original) The method of Claim 1, wherein the IBD is:
a) Crohn's disease; or
b) ulcerative colitis.
- 4-5. (Cancelled)
6. (Previously presented) The method of Claim 1, wherein the antagonist antibody or antigen binding fragment thereof comprises:
a) a polyclonal antibody;
b) a monoclonal antibody;
c) a humanized antibody; or
d) an Fab, Fv, or F(ab')₂ fragment.
- 7-21. (Cancelled)
22. (Previously presented) The method of Claim 3, wherein the IBD is Crohn's disease.

23. (Previously presented) The method of Claim 3, wherein the IBD is ulcerative colitis.
24. (Previously presented) The method of Claim 6, wherein the antagonist antibody or antigen binding fragment thereof comprises a monoclonal antibody.
25. (Previously presented) The method of Claim 6, wherein the antagonist antibody or antigen binding fragment thereof comprises a humanized antibody.
26. (Previously presented) The method of Claim 6, wherein the antagonist antibody or antigen binding fragment thereof comprises an Fab, Fv, or F(ab')₂ fragment.